| __timestamp | Amphastar Pharmaceuticals, Inc. | Novavax, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 19928000 |
| Thursday, January 1, 2015 | 46974000 | 30842000 |
| Friday, January 1, 2016 | 47298000 | 46527000 |
| Sunday, January 1, 2017 | 50918000 | 34451000 |
| Monday, January 1, 2018 | 58044000 | 34409000 |
| Tuesday, January 1, 2019 | 63109000 | 34417000 |
| Wednesday, January 1, 2020 | 65157000 | 145290000 |
| Friday, January 1, 2021 | 68920000 | 298358000 |
| Saturday, January 1, 2022 | 66592000 | 488691000 |
| Sunday, January 1, 2023 | 80393000 | 468946000 |
Unlocking the unknown
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Amphastar Pharmaceuticals, Inc. and Novavax, Inc. offer a fascinating study in contrasts from 2014 to 2023. Amphastar's SG&A expenses grew steadily, peaking at approximately 80 million in 2023, a 99% increase from 2014. Meanwhile, Novavax's expenses skyrocketed, especially post-2020, reaching nearly 490 million in 2022, a staggering 2,350% rise from 2014. This surge coincides with Novavax's pivotal role in COVID-19 vaccine development, highlighting how strategic shifts can dramatically impact financials. Amphastar's more consistent growth reflects a stable business model, while Novavax's volatility underscores the high stakes of innovation. Understanding these trends offers valuable insights into the financial strategies of biotech firms navigating a rapidly evolving landscape.
Selling, General, and Administrative Costs: argenx SE vs Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Exelixis, Inc. vs Novavax, Inc. Trends and Insights
Lantheus Holdings, Inc. and Novavax, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Novavax, Inc.
Ultragenyx Pharmaceutical Inc. and Novavax, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Ligand Pharmaceuticals Incorporated vs Novavax, Inc.
Agios Pharmaceuticals, Inc. vs Novavax, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
MannKind Corporation and Novavax, Inc.: SG&A Spending Patterns Compared